8 individuals charged in $157M compounding pharmacy fraud scheme

Eight Florida residents were charged in an indictment unsealed Tuesday for their alleged participation in a multi-million dollar fraud scheme, according to the Department of Justice.

Advertisement

Each of the eight men were charged with 12 counts of conspiracy to commit healthcare fraud and three counts of money laundering, according to the report.

According to the indictment, the co-conspirators allegedly used New Port Richey, Fla.-based A to Z Pharmacy, along with other pharmacies in the New Port Richey and Miami areas, to submit false and fraudulent reimbursement claims for prescription compounded medications to Medicare and Tricare.

The indictment said the prescriptions were not based on legitimate provider recommendations. The reimbursement claims were allegedly based on prescriptions generated as a result of illegal kickbacks and bribes and a misuse of patient information, according to the report.

Through the scheme, the defendants allegedly submitted approximately $633 million in claims for prescription compounded medications and received roughly $157 million in reimbursement based on the claims, according to the report.

The co-nspirators allegedly relied on shell companies to transfer and disburse the money in order to hide their involvement in the scheme, according to the indictment.

More articles on legal and regulatory issues:
Carolinas HealthCare asks court to dismiss antitrust lawsuit
Ex-Birmingham Health Care CFO sentenced in $11M fraud
Fake cruise ship physician sentenced to 3 years in prison

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.